CVS Caremark reports roughly $1.5 billion in gross savings and growing employer interest in biosimilars. The report gives no added CVS sales or profit, so it does not establish a change in CVS's outlook.
The savings show the program is being used, and employer interest may help it spread. But the report does not say CVS earned more from it or gained sales. It does not establish a change in CVS's business outlook.
Follow CVS Health (CVS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for CVS